Novo Nordisk’s Expansion in the U.S. to Tackle Diabetes and Metabolic Disorders

Novo Nordisk, a global pharmaceutical company, is making strides in its mission to find a cure for diabetes and metabolic disorders. Led by Jacob Petersen, the company's senior vice president and head of global nucleic acid therapies, Novo Nordisk is dedicated to addressing the challenges faced by patients with chronic diseases like diabetes.


Novo Nordisk, a global pharmaceutical company, is making strides in its mission to find a cure for diabetes and metabolic disorders. Led by Jacob Petersen, the company's senior vice president and head of global nucleic acid therapies, Novo Nordisk is dedicated to addressing the challenges faced by patients with chronic diseases like diabetes.

A Personal Mission


Petersen's personal connection to diabetes through his daughter's diagnosis has fueled his passion for finding a cure. He acknowledges the daily struggles that patients face and emphasizes the need for better treatment options. Novo Nordisk's ultimate goal is to find a cure for diabetes, a vision that drives the entire company forward.

The Reader's Guide

Expanding Research and Development


Novo Nordisk recently celebrated the opening of a new space within its U.S. Research and Early Development Hub in Greater Boston. This expansion includes cutting-edge facilities for Global Nucleic Acid Therapies and Advanced Drug Delivery R&D groups. The company is committed to growing its presence in the U.S. and investing in innovative research to tackle complex diseases.

A Hub of Innovation


With a focus on gene therapy, gene editing, and RNA interference, Novo Nordisk's Global Nucleic Acid Therapies team is at the forefront of developing novel treatments. By combining research capabilities with strategic partnerships and cutting-edge technologies, the company aims to revolutionize the field of healthcare.

Driving Growth and Collaboration


Novo Nordisk's strategic acquisitions, including Dicerna and Forma Therapeutics, have expanded its research capabilities and target space. These partnerships have enabled the company to explore new modalities beyond traditional proteins and peptides, opening up possibilities for addressing a wider range of diseases.

A Commitment to Patients


Through its long-term vision and dedication to research, Novo Nordisk is paving the way for groundbreaking treatments in diabetes, obesity, cardiovascular, and rare blood diseases. By leveraging the expertise of its team and collaborating with external partners, the company is making significant strides in improving patient outcomes.

Embracing Innovation in the Biopharma Industry


As part of the thriving biopharma community in Greater Boston, Novo Nordisk is poised to capitalize on the region's rich ecosystem of talent and resources. By staying at the forefront of innovation and driving collaboration, the company is positioning itself as a leader in the fight against chronic diseases.

In conclusion, Novo Nordisk's expansion in the U.S. represents a bold step towards transforming the landscape of healthcare. With a focus on research excellence, patient-centric innovation, and strategic partnerships, the company is driving towards a future where diabetes and metabolic disorders are no longer a daily struggle for patients.